Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
US5840305A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 14, 1996 |
| Grant date | Nov 24, 1998 |
| Priority date | — |
| Expiry date | Mar 14, 2016 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of HIV-infection using cyclophilin A and its corresponding human cellular binding partner or receptor as a target for intervention. The present invention relates to the use of exogenous or engrafted sources of cyclophilins, anti-cyclophilin antibodies, cyclophilin decoys, soluble forms of cyclophilin-binding partners and small molecules which are supplied extracellularly, and act presumably by interrupting the binding of cyclophilin A with its cellular binding partner(s) or receptor(s) as a treatment for HIV-infection. The present invention further relates to the use of forms of cyclosporin A that have been derivatized by bulky or charged substituents to inhibit cellular uptake and minimize their immunosuppressive activities, which presumably act to disrupt cyclophilin binding to its cellular receptor, likewise as a treatment for HIV-infection. The present invention further relates to genetic constructs to interfere with production and release of cyclophilin and its cognate cellular binding partner(s), to treat HIV-infection. The present invention further relates to screening a…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.